By combining the technology of silicon microfabrication with traditional medical device design Temari is developing two next generation products addressing unmet needs, Enfold for aneurysm closure and Divera for flow diversion.
The FDA deems there is a critical need for further advancements in minimally invasive treatment of cerebral aneurysms. These new endovascular treatments qualify for US FDA 510(k) fast track status, lowering the barrier for the introduction of a new device.
The device expands from a highly compressed state to fill the volume of the aneurysm sac, promote rapid peri-procedural stasis and then thrombosis to “seal the neck” of the aneurysm.
The device offers a unique closed cell design for optimal porosity with options to be used alone or in combination with ENFOLD for basal aneurysms.